  Cytotoxic chemotherapy is a common treatment for advanced prostate cancer.
These tumors are also known to rely on angiogenesis, i.e., the growth of local
microvasculature via chemical signaling produced by the tumor. Thus, several
clinical studies have been investigating antiangiogenic therapy for advanced
prostate cancer, either as monotherapy or combined with standard cytotoxic
protocols. However, the complex genetic alterations promoting prostate cancer
growth complicate the selection of the best chemotherapeutic approach for each
patient's tumor. Here, we present a mathematical model of prostate cancer
growth and chemotherapy that may enable physicians to test and design
personalized chemotherapeutic protocols in silico. We use the phase-field
method to describe tumor growth, which we assume to be driven by a generic
nutrient following reaction-diffusion dynamics. Tumor proliferation and
apoptosis (i.e., programmed cell death) can be parameterized with
experimentally-determined values. Cytotoxic chemotherapy is included as a term
downregulating tumor net proliferation, while antiangiogenic therapy is modeled
as a reduction in intratumoral nutrient supply. Another equation couples the
tumor phase field with the production of prostate-specific antigen, which is an
extensively used prostate cancer biomarker. We prove the well-posedness of our
model and we run a series of representative simulations using an isogeometric
method to explore untreated tumor growth as well as the effects of cytotoxic
chemotherapy and antiangiogenic therapy, both alone and combined. Our
simulations show that our model captures the growth morphologies of prostate
cancer as well as common outcomes of cytotoxic and antiangiogenic mono and
combined therapy. Our model also reproduces the usual temporal trends in tumor
volume and prostate-specific antigen evolution observed in previous studies.
